Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis

被引:87
作者
Arca, Marcello [1 ]
Pigna, Giovanni [1 ]
Favoccia, Carla [1 ]
机构
[1] Univ Roma La Sapienza, Dipartimento Med Internae Specialita Med, I-00161 Rome, Italy
关键词
Atherogenic dyslipidemia; VLDL secretion; apoB metabolism; insulin resistance; APOLIPOPROTEIN-B; CHOLESTEROL EFFLUX; INSULIN-RESISTANCE; LDL CHOLESTEROL; SECRETION; ATHEROSCLEROSIS; LIPOPROTEINS; METABOLISM; CAPACITY; DISEASE;
D O I
10.2174/157016112803520864
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
引用
收藏
页码:684 / 686
页数:3
相关论文
共 22 条
[1]
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia [J].
Adiels, M ;
Borén, J ;
Caslake, MJ ;
Stewart, P ;
Soro, A ;
Westerbacka, J ;
Wennberg, B ;
Olofsson, SO ;
Packard, C ;
Taskinen, MR .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (08) :1697-1703
[2]
Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states [J].
Barrows, BR ;
Parks, EJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (04) :1446-1452
[3]
The physiological and molecular regulation of lipoprotein assembly and secretion [J].
Blasiole, Daniel A. ;
Davis, Roger A. ;
Attie, Alan D. .
MOLECULAR BIOSYSTEMS, 2007, 3 (09) :608-619
[4]
Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apoliproprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) [J].
Charlton-Menys, Valentine ;
Betteridge, D. John ;
Colhoun, Helen ;
Fuller, John ;
France, Michael ;
Hitman, Graham A. ;
Livingstone, Shona J. ;
Neil, H. Andrew W. ;
Newman, Connie B. ;
Szarek, Michael ;
DeMicco, David A. ;
Durrington, Paul N. .
CLINICAL CHEMISTRY, 2009, 55 (03) :473-480
[5]
PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice [J].
Chirieac, Doru V. ;
Davidson, Nicholas O. ;
Sparks, Charles E. ;
Sparks, Janet D. .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2006, 291 (03) :G382-G388
[6]
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance [J].
Choi, Sung Hee ;
Ginsberg, Henry N. .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2011, 22 (09) :353-363
[7]
Complexity in the secretory pathway: The assembly and secretion of apolipoprotein B-containing lipoproteins [J].
Fisher, EA ;
Ginsberg, HN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (20) :17377-17380
[8]
High density lipoprotein apolipoprotein Al kinetics in NIDDM: A stable isotope study [J].
Frenais, R ;
Ouguerram, K ;
Maugeais, C ;
Mahot, P ;
Maugere, P ;
Krempf, M ;
Magot, T .
DIABETOLOGIA, 1997, 40 (05) :578-583
[9]
Grundy Scott M, 2006, Clin Cornerstone, V8 Suppl 1, pS21, DOI 10.1016/S1098-3597(06)80005-0
[10]
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver [J].
Horton, JD ;
Goldstein, JL ;
Brown, MS .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (09) :1125-1131